This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/04/16

    Nplate (romiplostim) Phase III study in children with symptomatic immune thrombocytopenia.-Amgen

    Amgen has announced that The Lancet published results from a Phase III randomized, double-blind, placebo-controlled study of Nplate (romiplostim) in...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    16/12/18

    FDA approves sBLA for NPlate to treat pediatric patients one year of age and older with immune thrombocytopenia. Amgen.

    Amgen announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    19/10/19

    FDA approves sBLA for Nplate in immune thrombocytopenia.- Amgen

    Amgen announced that the FDA has approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate (romiplostim) to include new data...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    11/11/17

    CHMP recommends extension of Nplate indication to children for thrombocytopenic purpura. -Amgen.

    Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    25/08/15

    FDA approves label extension of use of Promacta (eltrombopag) to treat infants with chronic immune thrombocytopenia- Novartis

    Novartis announced that the FDA has approved an expanded use for Promacta (eltrombopag) to include children 1 year of age...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    21/12/18

    Amgen files sBLA for Nplate in adult ITP.- Amgen.

    Amgen announced the submission of a Supplemental Biologics License Application (sBLA) to the FDA for Nplate (romiplostim) to include the...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    25/03/24

    Sobi announces positive results from phase III study of Doptelet (avatrombopag) for treatment of children and adolescents with immune thrombocytopenia .

    Sobi announced positive results from the AVA-PED-301 study (NCT04516967), evaluating the efficacy and safety of avatrombopag (Doptelet) for the treatment of paediatric patients with immune thrombocytopenia (ITP) of at least 6 months’ duration.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/06/15

    FDA approves extension of use of Promacta (eltrombopag) to children for thrombocytopenia- Novartis

    Novartis announced that the FDA has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic...

    Blue test tubes arranged in a line, disappearing into the background
    News
    12/11/24

    First patient dosed in phase III study with Doptelet for treatment of ITP in children. SOBI

    Swedish Orphan Biovitrum AB (publ) (Sobi™) announced that the first patient has been dosed with Doptelet (avatrombopag), a thrombopoietin receptor agonist (TPO-RA), for treatment of immune thrombocytopenia (ITP) in pediatric patients.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    14/11/23

    Health Canada approves Doptelet (avatrombopag) to treat chronic immune thrombocytopenia

    Health Canada approved avatrombopag (doptelet, Sobi) to treat thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) and in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure

    See more